Neurofibroma development in NF1 - insights into tumour initiation

Trends in Cell Biology

Volumn 19, Issue 8, 2009, Pages 395-403

  Parrinello, Simona ^a   Lloyd, Alison C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; NEUROFIBROMIN; RAS PROTEIN; SEMAPHORIN; SEMAPHORIN 4F; UNCLASSIFIED DRUG;

CARCINOGENESIS; EMBRYO DEVELOPMENT; EPIGENETICS; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; INFLAMMATION; NERVE REGENERATION; NERVE SHEATH TUMOR; NEUROFIBROMA; NEUROFIBROMATOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHWANN CELL; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; TUMOR GROWTH;

ANIMALS; CELL DIFFERENTIATION; GENETIC ENGINEERING; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEUROFIBROMA; NEUROFIBROMATOSIS 1;

EID: 68549087163     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcb.2009.05.003     Document Type: Review

References (65)

1. Hahn W.C., and Weinberg R.A. Rules for making human tumor cells. N. Engl. J. Med. 347 (2002) 1593-1603
2. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
3. Parsons D.W., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008) 1807-1812
4. Jones S., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (2008) 1801-1806
5. Meyer N., and Penn L.Z. Reflecting on 25 years with MYC. Nat. Rev. Cancer 8 (2008) 976-990
6. Malumbres M., and Barbacid M. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3 (2003) 459-465
7. Rubin J.B., and Gutmann D.H. Neurofibromatosis type 1 - a model for nervous system tumour formation?. Nat. Rev. Cancer 5 (2005) 557-564
8. Riccardi V.M. Neurofibromatosis: Phenotype, Natural History and Pathogenesis (1992), The John Hopkins University Press, Baltimore and London
9. Cichowski K., and Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 104 (2001) 593-604
10. McClatchey A.I. Neurofibromatosis. Annu. Rev. Pathol 2 (2007) 191-216
11. Colman S.D., et al. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat. Genet. 11 (1995) 90-92
12. Serra E., et al. Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. Hum. Mol. Genet. 9 (2000) 3055-3064
13. Zhu Y., et al. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296 (2002) 920-922
14. Sheela S., et al. Angiogenic and invasive properties of neurofibroma Schwann cells. J. Cell Biol. 111 (1990) 645-653
15. Rutkowski J.L., et al. Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum. Mol. Genet. 9 (2000) 1059-1066
16. Kim H.A., et al. Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes. Oncogene 11 (1995) 325-335
17. DeClue J.E., et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69 (1992) 265-273
18. Basu T.N., et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356 (1992) 713-715
19. Jessen K.R., and Mirsky R. The origin and development of glial cells in peripheral nerves. Nat. Rev. Neurosci. 6 (2005) 671-682
20. Dong Z., et al. Schwann cell development in embryonic mouse nerves. J. Neurosci. Res. 56 (1999) 334-348
21. Kruger G.M., et al. Neural crest stem cells persist in the adult gut but undergo changes in self-renewal, neuronal subtype potential, and factor responsiveness. Neuron 35 (2002) 657-669
22. Fawcett J.W., and Keynes R.J. Peripheral nerve regeneration. Annu. Rev. Neurosci. 13 (1990) 43-60
23. Scherer, S. a.S., J. L. (2001) Axon-Schwann cell interactions during peripheral nerve degeneration and regeneration. Oxford: Oxford University Press
24. Alcantara Llaguno S., et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15 (2009) 45-56
25. Visvader J.E., and Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8 (2008) 755-768
26. Reya T., et al. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
27. Cho R.W., and Clarke M.F. Recent advances in cancer stem cells. Curr. Opin. Genet. Dev. 18 (2008) 48-53
28. Joseph N.M., et al. The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. Cancer Cell 13 (2008) 129-140
29. Wu J., et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell 13 (2008) 105-116
30. Zheng H., et al. Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation. Cancer Cell 13 (2008) 117-128
31. Riccardi V.M., and Lewis R.A. Penetrance of von Recklinghausen neurofibromatosis: a distinction between predecessors and descendants. Am. J. Hum. Genet. 42 (1988) 284-289
32. Easton D.F., et al. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am. J. Hum. Genet. 53 (1993) 305-313
33. Topilko P., et al. Krox-20 controls myelination in the peripheral nervous system. Nature 371 (1994) 796-799
34. Voiculescu O., et al. Expression pattern of a Krox-20/Cre knock-in allele in the developing hindbrain, bones, and peripheral nervous system. Genesis 26 (2000) 123-126
35. Corfas G., et al. Mechanisms and roles of axon-Schwann cell interactions. J. Neurosci. 24 (2004) 9250-9260
36. Chan J.R., et al. The polarity protein Par-3 directly interacts with p75NTR to regulate myelination. Science 314 (2006) 832-836
37. Taveggia C., et al. Neuregulin-1 type III determines the ensheathment fate of axons. Neuron 47 (2005) 681-694
38. Michailov G.V., et al. Axonal neuregulin-1 regulates myelin sheath thickness. Science 304 (2004) 700-703
39. Parrinello S., et al. NF1 loss disrupts Schwann cell-axonal interactions: a novel role for semaphorin 4F. Genes Dev. 22 (2008) 3335-3348
40. Encinas J.A., et al. Cloning, expression, and genetic mapping of Sema W, a member of the semaphorin family. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 2491-2496
41. Cohen R.I., et al. A role for semaphorins and neuropilins in oligodendrocyte guidance. J. Neurochem. 85 (2003) 1262-1278
42. Kruger R.P., et al. Semaphorins command cells to move. Nat. Rev. Mol. Cell Biol. 6 (2005) 789-800
43. Chen S., et al. Disruption of ErbB receptor signaling in adult non-myelinating Schwann cells causes progressive sensory loss. Nat. Neurosci. 6 (2003) 1186-1193
44. Le L.Q., and Parada L.F. Tumor microenvironment and neurofibromatosis type I: connecting the GAPs. Oncogene 26 (2007) 4609-4616
45. +/- mast cells. J. Clin. Invest. 112 (2003) 1851-1861
46. +/- mast cells induce neurofibroma like phenotypes through secreted TGF-β signaling. Hum. Mol. Genet. 15 (2006) 2421-2437
47. Wu M., et al. Tumorigenic properties of neurofibromin-deficient Schwann cells in culture and as syngrafts in Nf1 knockout mice. J. Neurosci. Res. 82 (2005) 357-367
48. +/-- and c-kit-dependent bone marrow. Cell 135 (2008) 437-448
49. Chen Z.L., et al. Peripheral regeneration. Annu. Rev. Neurosci. 30 (2007) 209-233
50. Hirata K., and Kawabuchi M. Myelin phagocytosis by macrophages and nonmacrophages during Wallerian degeneration. Microsc. Res. Tech. 57 (2002) 541-547
51. Harrisingh M.C., and Lloyd A.C. Ras/Raf/ERK signalling and NF1. Cell Cycle 3 (2004) 1255-1258
52. Harrisingh M.C., et al. The Ras/Raf/ERK signalling pathway drives Schwann cell dedifferentiation. EMBO J. 23 (2004) 3061-3071
53. Riccardi V.M. Cutaneous manifestation of neurofibromatosis: cellular interaction, pigmentation, and mast cells. Birth Defects Orig. Artic. Ser. 17 (1981) 129-145
54. Elenbaas B., and Weinberg R.A. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res. 264 (2001) 169-184
55. Tlsty T.D., and Coussens L.M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 1 (2006) 119-150
56. Kenny P.A., and Bissell M.J. Tumor reversion: correction of malignant behavior by microenvironmental cues. Int. J. Cancer 107 (2003) 688-695
57. Weaver V.M., et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137 (1997) 231-245
58. Kirshner J., et al. CEACAM1-4S, a cell-cell adhesion molecule, mediates apoptosis and reverts mammary carcinoma cells to a normal morphogenic phenotype in a 3D culture. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 521-526
59. Muschler J., et al. A role for dystroglycan in epithelial polarization: loss of function in breast tumor cells. Cancer Res. 62 (2002) 7102-7109
60. Boudreau N., et al. The embryonic environment and extracellular matrix suppress oncogenic transformation by Rous sarcoma virus in chick embryos. Mol. Cell. Diff. 3 (1995) 261-274
61. llmensee K. Reversion of malignancy and normalized differentiation of teratocarcinoma cells in chimeric mice. Basic Life Sci. 12 (1978) 3-25
62. McCullough K.D., et al. Plasticity of the neoplastic phenotype in vivo is regulated by epigenetic factors. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 15333-15338
63. Olumi A.F., et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59 (1999) 5002-5011
64. Riccardi V.M., and Margos V.A. Characteristics of skin and tumor fibroblasts from neurofibromatosis patients. Adv. Neurol. 29 (1981) 191-198
65. Zochodne D.W. Neurobiology of Peripheral Nerve Regeneration (2008), Cambridge University Press